These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29926072)

  • 1. [Research progress of histone deacetylase 6 inhibitors in the therapy of ischemic stroke].
    Zhang CC; Lu F; Liang JQ; Zhou YF
    Sheng Li Xue Bao; 2018 Jun; 70(3):301-309. PubMed ID: 29926072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Сlass II histone deacetylases in the post-stroke recovery period-expression, cellular, and subcellular localization-promising targets for neuroprotection.
    Demyanenko S; Berezhnaya E; Neginskaya M; Rodkin S; Dzreyan V; Pitinova M
    J Cell Biochem; 2019 Dec; 120(12):19590-19609. PubMed ID: 31264264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate.
    Demyanenko SV; Dzreyan VA; Uzdensky AB
    Brain Res Bull; 2020 Sep; 162():151-165. PubMed ID: 32592806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
    Guo Z; Zhang Z; Zhang Y; Wang G; Huang Z; Zhang Q; Li J
    Eur J Med Chem; 2021 Jun; 218():113383. PubMed ID: 33799069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents.
    Langley B; Gensert JM; Beal MF; Ratan RR
    Curr Drug Targets CNS Neurol Disord; 2005 Feb; 4(1):41-50. PubMed ID: 15723612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons.
    Iaconelli J; Xuan L; Karmacharya R
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30935091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery.
    Fessler EB; Chibane FL; Wang Z; Chuang DM
    Curr Pharm Des; 2013; 19(28):5105-20. PubMed ID: 23448466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
    Beyer M; Kiweler N; Mahboobi S; Krämer OH
    Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke.
    Faggi L; Pignataro G; Parrella E; Porrini V; Vinciguerra A; Cepparulo P; Cuomo O; Lanzillotta A; Mota M; Benarese M; Tonin P; Annunziato L; Spano P; Pizzi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updating a Strategy for Histone Deacetylases and Its Inhibitors in the Potential Treatment of Cerebral Ischemic Stroke.
    Xu Y; Wang Q; Chen J; Ma Y; Liu X
    Dis Markers; 2020; 2020():8820803. PubMed ID: 32963637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window.
    Lanzillotta A; Pignataro G; Branca C; Cuomo O; Sarnico I; Benarese M; Annunziato L; Spano P; Pizzi M
    Neurobiol Dis; 2013 Jan; 49():177-89. PubMed ID: 22971966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
    Van Helleputte L; Kater M; Cook DP; Eykens C; Rossaert E; Haeck W; Jaspers T; Geens N; Vanden Berghe P; Gysemans C; Mathieu C; Robberecht W; Van Damme P; Cavaletti G; Jarpe M; Van Den Bosch L
    Neurobiol Dis; 2018 Mar; 111():59-69. PubMed ID: 29197621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury.
    Baltan S; Morrison RS; Murphy SP
    Neurotherapeutics; 2013 Oct; 10(4):798-807. PubMed ID: 23881453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibiting histone deacetylase 6 partly protects cultured rat cortical neurons from oxygen‑glucose deprivation‑induced necroptosis.
    Yuan L; Wang Z; Liu L; Jian X
    Mol Med Rep; 2015 Aug; 12(2):2661-7. PubMed ID: 25976407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation.
    Wang Z; Leng Y; Wang J; Liao HM; Bergman J; Leeds P; Kozikowski A; Chuang DM
    Sci Rep; 2016 Jan; 6():19626. PubMed ID: 26790818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
    Gray SG; Dangond F
    Epigenetics; 2006; 1(2):67-75. PubMed ID: 17998807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.